ICAM4 and acute myeloid leukemia: Our LR pair-based scoring system, LR.score, demonstrated significant potential in predicting patient responses to both traditional chemotherapy and emerging targeted therapies, with a particular emphasis on its association with T-cell dysfunction and the downregulation of specific markers such as CLEC11A, ICAM4, ITGA4, and AVP in AML.